| ~(131)I-Rituximab对B细胞淋巴瘤的放射免疫导向治疗的实验研究 |
| |
| 引用本文： | 智生芳,樊卫,王国慧,刘长征,何军芳.~(131)I-Rituximab对B细胞淋巴瘤的放射免疫导向治疗的实验研究[J].实用医技杂志,2007,14(15):1961-1963. |
| |
| 作者姓名： | 智生芳 樊卫 王国慧 刘长征 何军芳 |
| |
| 作者单位： | 1. 中山大学肿瘤防治中心,广东,广州,510060
2. 中山大学基础医学院,广东,广州,510060 |
| |
| 基金项目： | 中山大学肿瘤防治中心重点课题建设项目 |
| |
| 摘 要： | 目的:探讨放射性核素131I标记Rituximab及131I-Rituximab对B细胞淋巴瘤细胞进行放射免疫导向治疗的可行性。方法:采用氯胺-T法制备131I-Rituximab,采用CCK-8法观察131I-Rituximab对Raji细胞的抑制作用,对照组为131I、Rituximab组。结果:131I-Rituximab标记率在92%以上,放化学纯度达98%以上。CCK-8法表明131I-Rituximab对Raji细胞的抑瘤率与131I组和Rituximab组的抑瘤率有统计学差异(P<0.01)。结论:提示131I-Rituximab对人B细胞淋巴瘤的放射免疫导向治疗具有可行性。
|
| 关 键 词： | B细胞淋巴瘤 Rituximab 131I CCK-8 |
Experimental Study of the Labeling Method and Inhibitive Effects on Non-Hodgkin's B-cell Lymphoma Cells of 131I-Rituximab |
| |
| ZHI Sheng-fang,FAN Wei,WANG Guo-hui,LIU Chang-zheng,HE Jun-fang.Experimental Study of the Labeling Method and Inhibitive Effects on Non-Hodgkin''s B-cell Lymphoma Cells of 131I-Rituximab[J].Journal of Practical Medical Techniques,2007,14(15):1961-1963. |
| |
| Authors: | ZHI Sheng-fang FAN Wei WANG Guo-hui LIU Chang-zheng HE Jun-fang |
| |
| Abstract: | Objective To investigate the feasibility of targeted on non-Hodgkin Lymphoma with 131I-Rituximab.Methods Rituximab is a kind of monoclonal antibody to NHL.The 131I-Rituximab was prepared by Tosylchloramide Sodium labeling way.The CCK-8 method was used to determine the inhibitive effect of the 131I-Rituximab.The control group were 131I、Rituximab.Results The labeling yield of 131I-Rituximab was above 92%. The results of CCK-8 method showed that the inhibitive effect of 131I-Rituximab was much stronger than 131I and Rituximab (P<0.01).Conclusion 131I-Rituximab provides a promising may of targeted therapy on non-Hodgkin's B-cell lymphoma . |
| |
| Keywords: | Rituximab 131I CCK-8 |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
